Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHVN NYSE:EBS NASDAQ:FOLD NASDAQ:QURE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$13.56-0.1%$10.35$7.48▼$18.57$2.04B1.353.35 million shs6.46 million shsEBSEmergent Biosolutions$7.99-0.1%$8.40$5.61▼$14.06$412.77M2.33868,513 shs2.23 million shsFOLDAmicus Therapeutics$14.49$14.42$5.51▼$14.50$4.55B0.482.62 million shs5.29 million shsQUREuniQure$46.29$24.74$8.73▼$71.50$2.92B0.982.36 million shs4.85 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven0.00%+19.57%+42.98%+52.00%-5.67%EBSEmergent Biosolutions0.00%-3.95%-4.36%-2.29%+26.75%FOLDAmicus Therapeutics0.00%0.00%0.00%+0.42%+152.88%QUREuniQure0.00%+67.90%+86.95%+187.69%+206.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$13.56-0.1%$10.35$7.48▼$18.57$2.04B1.353.35 million shs6.46 million shsEBSEmergent Biosolutions$7.99-0.1%$8.40$5.61▼$14.06$412.77M2.33868,513 shs2.23 million shsFOLDAmicus Therapeutics$14.49$14.42$5.51▼$14.50$4.55B0.482.62 million shs5.29 million shsQUREuniQure$46.29$24.74$8.73▼$71.50$2.92B0.982.36 million shs4.85 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven0.00%+19.57%+42.98%+52.00%-5.67%EBSEmergent Biosolutions0.00%-3.95%-4.36%-2.29%+26.75%FOLDAmicus Therapeutics0.00%0.00%0.00%+0.42%+152.88%QUREuniQure0.00%+67.90%+86.95%+187.69%+206.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHVNBiohaven 2.71Moderate Buy$22.2764.17% UpsideEBSEmergent Biosolutions 2.40Hold$12.0050.11% UpsideFOLDAmicus Therapeutics 2.08Hold$14.560.50% UpsideQUREuniQure 2.65Moderate Buy$58.9227.28% UpsideCurrent Analyst Ratings BreakdownLatest BHVN, FOLD, EBS, and QURE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026QUREuniQure Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $65.006/18/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/18/2026QUREuniQure Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $70.006/18/2026QUREuniQure The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$14.00 ➝ $46.006/18/2026QUREuniQure BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$25.00 ➝ $65.006/17/2026QUREuniQure BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingPositive6/17/2026QUREuniQure Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$61.006/2/2026BHVNBiohaven Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/2/2026EBSEmergent Biosolutions UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/2/2026EBSEmergent Biosolutions BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/27/2026BHVNBiohaven Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHVNBiohavenN/AN/AN/AN/A$0.39 per shareN/AEBSEmergent Biosolutions$742.90M0.56$3.67 per share2.18$9.95 per share0.80FOLDAmicus Therapeutics$634.21M7.17$0.06 per share234.67$0.87 per share16.66QUREuniQure$16.10M181.34N/AN/A$3.19 per share14.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHVNBiohaven-$738.82M-$5.67N/AN/AN/AN/A-866.46%-137.99%8/10/2026 (Estimated)EBSEmergent Biosolutions$52.60M-$0.28N/AN/AN/A-1.27%10.76%4.22%8/5/2026 (Estimated)FOLDAmicus Therapeutics-$27.11M-$0.08N/A18.82N/A-4.27%4.15%1.09%N/AQUREuniQure-$198.97M-$3.48N/AN/AN/A-1,154.42%-145.81%-27.15%8/4/2026 (Estimated)Latest BHVN, FOLD, EBS, and QURE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026QUREuniQure-$0.88-$0.85+$0.03-$0.85$5.21 million$3.56 million5/4/2026Q1 2026BHVNBiohaven-$0.86-$0.88-$0.02-$0.88$0.27 millionN/A4/30/2026Q1 2026EBSEmergent Biosolutions-$0.25$0.21+$0.46$0.07$145.00 million$156.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHVNBiohavenN/AN/AN/AN/AN/AEBSEmergent BiosolutionsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHVNBiohaven1.877.417.41EBSEmergent Biosolutions1.104.292.08FOLDAmicus Therapeutics1.432.841.88QUREuniQure0.3310.4010.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHVNBiohaven88.78%EBSEmergent Biosolutions78.40%FOLDAmicus TherapeuticsN/AQUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipBHVNBiohaven13.80%EBSEmergent Biosolutions6.00%FOLDAmicus Therapeutics2.20%QUREuniQure4.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHVNBiohaven239150.56 million129.78 millionOptionableEBSEmergent Biosolutions2,42051.60 million48.50 millionOptionableFOLDAmicus Therapeutics480314.00 million307.09 millionOptionableQUREuniQure50063.07 million60.13 millionOptionableBHVN, FOLD, EBS, and QURE HeadlinesRecent News About These CompaniesUniQure to seek approval of Huntington’s gene therapy after FDA U-turnJune 20 at 5:45 PM | msn.com146,498 Shares in uniQure N.V. $QURE Bought by Flax Pond Capital LLCJune 20 at 4:07 AM | marketbeat.comuniQure N.V. $QURE Stock Position Raised by Avoro Capital Advisors LLCJune 20 at 3:21 AM | marketbeat.comuniQure (QURE) Stock Could Be 49% Undervalued After FDA AMT 130 UpdateJune 19 at 4:42 PM | finance.yahoo.comuniQure (QURE) Is Up 67.9% After FDA Backs AMT-130 Data For Accelerated Approval PathJune 19 at 4:42 PM | finance.yahoo.comQURE Soars as FDA Backs AMT-130 Data for Accelerated ApprovalJune 19 at 3:20 PM | zacks.comuniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe EpilepsyJune 19 at 7:05 AM | globenewswire.comThe Other Shoe Drops: uniQure Shares Plans To Submit Licensing Application With The FDA for AMT-130June 18 at 11:04 PM | en.hdbuzz.netEuniQure Soars After FDA's U-Turn Opens Accelerated Approval Pathway for Huntington's TherapyJune 18 at 6:51 PM | benzinga.comUniQure (QURE) Soars 78% on AMT-130 ProgressJune 18 at 6:03 PM | finance.yahoo.comUniQure to seek approval for Huntington's therapy after FDA U-turn, shares skyrocketJune 18 at 6:03 PM | msn.comuniQure Stock Looks Drastically Undervalued After Upbeat FDA MeetingJune 18 at 1:51 PM | barchart.comUniQure: AMT-130's FDA Path Reaffirms My Bull CaseJune 18 at 10:06 AM | seekingalpha.comuniQure (NASDAQ:QURE) Upgraded to Overweight at BarclaysJune 18 at 9:02 AM | marketbeat.comuniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?June 18 at 8:31 AM | zacks.comuniQure (NASDAQ:QURE) Insider Jeannette Potts Sells 5,237 SharesJune 18 at 8:13 AM | insidertrades.comEversept Partners LP Has $1.50 Million Stock Holdings in uniQure N.V. $QUREJune 18 at 5:45 AM | marketbeat.comClearline Capital LP Takes Position in uniQure N.V. $QUREJune 18 at 5:09 AM | marketbeat.comArtia Global Partners LP Boosts Stake in uniQure N.V. $QUREJune 18 at 4:24 AM | marketbeat.comuniQure N.V. (NASDAQ:QURE) Receives Consensus Rating of "Moderate Buy" from BrokeragesJune 18 at 2:09 AM | americanbankingnews.comuniQure N.V. (NASDAQ:QURE) Given Average Recommendation of "Moderate Buy" by AnalystsJune 18 at 2:07 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHVN, FOLD, EBS, and QURE Company DescriptionsBiohaven NYSE:BHVN$13.56 -0.01 (-0.05%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$13.45 -0.11 (-0.84%) As of 06/18/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Emergent Biosolutions NYSE:EBS$7.99 -0.01 (-0.08%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$7.86 -0.14 (-1.74%) As of 06/18/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Amicus Therapeutics NASDAQ:FOLDAmicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.uniQure NASDAQ:QURE$46.29 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$46.52 +0.23 (+0.50%) As of 06/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
